Cipla Company Profile

✉ Email this page to a colleague

CIPLA has ninety-two approved drugs.

There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.

There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and thirty-nine supplementary protection certificates in seventeen countries.

International Patents:	30
US Patents:	6
Tradenames:	81
Ingredients:	81
NDAs:	92
Patent Litigation for Cipla:	See patent lawsuits for Cipla
PTAB Cases with Cipla as petitioner:	See PTAB cases with Cipla as petitioner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla	DEFERASIROX	deferasirox	GRANULE;ORAL	215026-002	Feb 23, 2022	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Cipla	LENALIDOMIDE	lenalidomide	CAPSULE;ORAL	210435-002	Sep 6, 2022	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Cipla	EMTRICITABINE	emtricitabine	CAPSULE;ORAL	091168-001	Jul 2, 2018	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		RX	Yes	Yes	8,822,424	⤷ Try a Trial	Y			⤷ Try a Trial
Cipla	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	211291-002	May 28, 2019		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Cipla	CELECOXIB	celecoxib	CAPSULE;ORAL	207446-002	Sep 23, 2015	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Cipla	CINACALCET HYDROCHLORIDE	cinacalcet hydrochloride	TABLET;ORAL	208915-003	Mar 8, 2018	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2924034	1990024-0	Sweden	⤷ Try a Trial	PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE; REG. NO/DATE: EU/1/18/1333 20181126
2137537	122014000069	Germany	⤷ Try a Trial	PRODUCT NAME: DIMETHYLFUMARAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
0382526	19675032	Germany	⤷ Try a Trial	PRODUCT NAME: LAMIVUDINE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH GEEIGNETEN SALZES; NAT. REGISTRATION NO/DATE: EU/1/96/015/001-002 19960808 FIRST REGISTRATION: CH 53662 53663 19960228
0443983	2007C/043	Belgium	⤷ Try a Trial	PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
2666774	LUC00167	Luxembourg	⤷ Try a Trial	PRODUCT NAME: RELEBACTAM, EVENTUELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE, EVENTUELLEMENT SOUS FORME DE SEL DE SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/19/1420 20200217
2203431	92666	Luxembourg	⤷ Try a Trial	PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
2487166	PA2016038	Lithuania	⤷ Try a Trial	PRODUCT NAME: ELVITEGRAVIRAS + KOBICISTATAS + EMTRICITABINAS + TENOFOVIRALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/15/1061 20151119
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.